Literature DB >> 30103906

Effect of Atrial Fibrillation and Mitral Valve Gradients on Response to Percutaneous Mitral Valve Repair With the MitraClip System.

Maximilian Spieker1, Katharina Hellhammer1, Jens Spießhöfer1, Stratis Katsianos1, Jan Balzer2, Tobias Zeus1, Patrick Horn1, Malte Kelm3, Ralf Westenfeld4.   

Abstract

Both pre-existing atrial fibrillation (AF) and mitral valve pressure gradients (MVPG) created by MitraClip implantation have demonstrated predictive power for unfavorable outcomes. Therefore, we aimed to assess the impact of MVPG following MitraClip on outcomes in patients with and without AF. A total of 200 patients who underwent MitraClip implantation in our institution were enrolled. Echocardiography was obtained before and after the procedure. The primary endpoint of the study was all-cause mortality 1-year after MitraClip implantation. Secondary end points were clinical improvements in NYHA functional class and reduction in MR severity after MitraClip implantation. Two hundred patients (74 ± 10 years, left ventricular ejection fraction 41% ± 14%, logistic EuroSCORE I 21 ± 15) were enrolled into the final analysis. One hundred twelve patients (56%) had pre-existing AF. One-year all-cause mortality was 17% without any differences between patients with or without pre-existing AF. Comparing postprocedural MVPG of surviving and deceased patients, deceased patients with pre-existing AF exhibited significantly elevated postprocedural MVPG compared with surviving patients without AF (4.8 ± 2.1 mm Hg vs 3.6 ± 1.8 mm Hg; p = 0.010). ROC analysis and Kaplan-Meier survival curves identified significantly reduced survival in AF patients with postprocedural MVPG above 4.0 mm Hg (p = 0.011). After MitraClip, a MVPG above 4.0 mm Hg in patients with pre-existing AF was a significant outcome predictor in univariate and multivariate analysis. In conclusion, we identified a high-risk cohort characterized by postprocedural MVPG above 4.0 mm Hg and pre-existing AF predicting poor long-term outcome.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2018        PMID: 30103906     DOI: 10.1016/j.amjcard.2018.06.050

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  4 in total

Review 1.  Impact of atrial fibrillation on the outcomes of transcatheter mitral valve repair using MitraClip: a systematic review and meta-analysis.

Authors:  Siddharth Shah; Vijay Raj; Mahmoud Abdelghany; Carlos Mena-Hurtado; Sana Riaz; Siddharth Patel; Howard Wiener; Debanik Chaudhuri
Journal:  Heart Fail Rev       Date:  2020-11-10       Impact factor: 4.214

2.  Real-world anticoagulatory treatment after percutaneous mitral valve repair using MitraClip: a retrospective, observational study on 1300 patients.

Authors:  Christopher Hohmann; Marion Ludwig; Jochen Walker; Christos Iliadis; Jan-Hendrik Schipper; Stephan Baldus; Roman Pfister
Journal:  Clin Res Cardiol       Date:  2022-02-26       Impact factor: 6.138

3.  Impact of paroxysmal versus non-paroxysmal atrial fibrillation on outcomes in patients undergoing transcatheter mitral valve repair.

Authors:  Kishorbhai Gangani; Haytham Alkhaimy; Nikita Patil; Kranthi Sitammagari; Poonam Bhyan; Sameer Arora; John P Vavalle
Journal:  Cardiovasc Diagn Ther       Date:  2020-02

4.  Impact of atrial fibrillation on outcomes of patients treated by transcatheter mitral valve repair: A systematic review and meta-analysis.

Authors:  Fuqiang Sun; Honghao Liu; Qi Zhang; Fanfan Lu; Haibo Zhan; Jiawei Zhou
Journal:  Medicine (Baltimore)       Date:  2020-10-02       Impact factor: 1.817

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.